logo.png
LIDDS Interim report January – September 2021
November 22, 2021 10:45 ET | LIDDS AB
JANUARY – SEPTEMBER 2021 Net sales amounted to MSEK 1.2 (0.0)Operating expenses amounted to MSEK -29,5 (-19,8)Profit/loss before and after tax amounted to MSEK -28.4 (-19.8)Earnings per share...
logo.png
Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
November 17, 2021 04:00 ET | LIDDS AB
November 17, 2021 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS UPPSALA, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for...
logo.png
LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
November 15, 2021 05:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Johan Harmenberg has been appointed Chief Medical Officer (CMO) of LIDDS AB. Johan Harmenberg has extensive experience from the pharmaceutical...
logo.png
NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
October 04, 2021 13:30 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001) with the primary objective to study safety of...
logo.png
LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
September 28, 2021 10:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in Russia...
logo.png
LIDDS Interim report January – June 2021
August 26, 2021 02:30 ET | LIDDS AB
JANUARY – JUNE 2021 Net sales amounted to MSEK 0.8 (0.0)Operating expenses amounted to MSEK -21.3 (-13.3)Profit/loss before and after tax amounted to MSEK -20.6 (-13.3)Earnings per share amounted...
logo.png
LIDDS – subscription of warrants
July 06, 2021 08:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) The Annual General Meeting held on May 17, 2021, resolved to establish a warrants-based incentive programme 2021/2024 for the CEO and other key-persons in the...
LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
June 02, 2021 16:00 ET | LIDDS AB
NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY, WITHIN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR IN ANY OTHER JURISDICTION...
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr
June 02, 2021 16:00 ET | LIDDS AB
EJ FÖR DISTRIBUTION DIREKT ELLER INDIREKT, INOM ELLER TILL AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER USA, ELLER I NÅGON ANNAN JURISDIKTION DÄR...
logo.png
LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer
June 01, 2021 02:45 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Jenni Björnulfson has been appointed new Chief Financial Officer (CFO) of LIDDS AB succeeding Anja Peters, who will leave LIDDS at the end of...